

Traceable Opioid Material® Kits (TOM Kits®)

The Centers for Disease Control and Prevention (CDC) has developed Traceable Opioid Material® Kits (TOM Kits®) to support laboratory detection of current and emerging opioids as well as common co-drugs found in fentanyl-containing samples. The CDC has contracted Cayman, an ISO-accredited reference material producer, to manufacture and distribute TOM Kits®.

Overview

TOM Kits® are a collection of reference standards for screening emerging drugs of concern in seized drug or toxicological casework. The full set includes reference standards for 250 synthetic opioid, 80 co-drugs, and isotopically labeled versions of select compounds.

Increase Detection Capabilities

Widens the scope of mass spectrometry and immunoassay screening methods

Convenient Format

Individual standards are packaged in a 96-well Matrix™ tube rack format

Free of Charge

Available to qualified labs



TOM Kits® support government, clinical, and academic research labs performing:

- Seized drug sample testing
- Toxicology testing & other biological sample analysis
- Environmental sample testing
- Drug pharmacology & pharmacokinetics research
- Public health surveillance & drug monitoring
- Analytical method development

The TOM Kits® product line are not for diagnostic use.



TOM Kits®

Traceable Opioid Materials, TOM Kits, and the TOM Kits Logo are marks of the US Dept. of Health and Human Services



U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION

The mark "CDC" is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.

Apply Now



TOM Kits® Available from Cayman

FAS Kit & FAS Kit - Emergent Panels

The Fentanyl Analog Screening (FAS) Kit and FAS Kit - Emergent Panels V1-V4 contain reference standards that enable labs to screen for 250 synthetic opioids. They are available to qualified labs worldwide.

Coverage includes:

- Fentanyl analogs
- Nitazenes
- Cinnamylpiperazines
- Utopioids



EDP & EDP-IS Kits

The Emergent Drug Panel (EDP) and EDP - Version 1 (EDP-V1) expand coverage to co-drugs that may be found in fentanyl-containing samples. They are available to qualified labs in the U.S. or its territories.

Coverage includes:

- Synthetic opioids
- Stimulants
- Hallucinogens
- Benzodiazepines
- Synthetic cannabinoids
- Xylazine

The Emergent Drug Panel - Internal Standard (EDP-IS) contains isotopically labeled versions of select compounds included in the EDP and FAS Kits for use as internal standards in mass spectrometry-based analyses. Available to qualified labs in the U.S. or its territories.

